Literature DB >> 8384112

Selective action of two aporphines at alpha 1-adrenoceptors and potential-operated Ca2+ channels.

M D Ivorra1, S Chuliá, C Lugnier, M P D'Ocon.   

Abstract

Contractions evoked by noradrenaline (1 microM) or a depolarizing solution of 60 mM KCl were concentration dependently depressed by the aporphine alkaloids (S)-boldine and (R)-apomorphine in rat aorta. Both drugs had a greater inhibitory potency on the contraction elicited by noradrenaline. Dose-response curves for noradrenaline were shifted to the right in presence of (S)-boldine. (R)-Apomorphine acted by a complex mechanism at alpha 1-adrenoceptors and its inhibitory effect was irreversible. The conformational features of these alkaloids may explain their different behaviour at alpha 1-adrenoceptors. In Ca(2+)-free solution, the alkaloids inhibited the contraction evoked by noradrenaline but did not modify (apomorphine) or increase (boldine) the contractile response induced by caffeine. Both alkaloids interacted with [3H]prazosin binding and with the benzothiazepine binding site of the Ca2+ entry receptor complex but had no effect at the dihydropyridine binding site in the rat cerebral cortex. Both drugs showed some selectivity as inhibitors of [3H]prazosin binding as opposed to [3H]d-cis diltiazem binding. (R)-Apomorphine slightly inhibited one of the two forms of the Ca(2+)-independent, low Km cyclic AMP-phosphodiesterase (type IV), whereas it did not have a significant effect on the other phosphodiesterase forms. (S)-Boldine had negligible inhibitory effects on all phosphodiesterase forms. The present study provides evidence that (S)-boldine and (R)-apomorphine have interesting properties as Ca2+ entry blockers (through the benzothiazepine receptor site in the Ca2+ channel) and at alpha 1-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384112     DOI: 10.1016/0014-2999(93)90445-n

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Molecular modeling study of diltiazem mimics at L-type calcium channels.

Authors:  K J Schleifer; E Tot
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

2.  The effect of S-(+)-boldine on the alpha 1-adrenoceptor of the guinea-pig aorta.

Authors:  S Chuliá; J Moreau; E Naline; M A Noguera; M D Ivorra; M P D'Ocón; C Advenier
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

3.  Pharmacophore modelling of structurally unusual diltiazem mimics at L-type calcium channels.

Authors:  K J Schleifer; E Tot
Journal:  J Comput Aided Mol Des       Date:  2000-07       Impact factor: 3.686

4.  A possible structural determinant of selectivity of boldine and derivatives for the alpha 1A-adrenoceptor subtype.

Authors:  Y Madrero; M Elorriaga; S Martinez; M A Noguera; B K Cassels; P D'Ocon; M D Ivorra
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

5.  Mechanism of the cardiovascular activity of laudanosine: comparison with papaverine and other benzylisoquinolines.

Authors:  S Chuliá; M D Ivorra; C Lugnier; E Vila; M A Noguera; P D'Ocon
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

6.  Screening of the Pan-African natural product library identifies ixoratannin A-2 and boldine as novel HIV-1 inhibitors.

Authors:  Ian Tietjen; Fidele Ntie-Kang; Philip Mwimanzi; Pascal Amoa Onguéné; Margaret A Scull; Thomas Oyebode Idowu; Abiodun Oguntuga Ogundaini; Luc Mbaze Meva'a; Berhanu M Abegaz; Charles M Rice; Kerstin Andrae-Marobela; Mark A Brockman; Zabrina L Brumme; David Fedida
Journal:  PLoS One       Date:  2015-04-01       Impact factor: 3.240

7.  Assessment of Insecticidal Activity of Benzylisoquinoline Alkaloids from Chilean Rhamnaceae Plants against Fruit-Fly Drosophila melanogaster and the Lepidopteran Crop Pest Cydia pomonella.

Authors:  Soledad Quiroz-Carreño; Edgar Pastene-Navarrete; Cesar Espinoza-Pinochet; Evelyn Muñoz-Núñez; Luis Devotto-Moreno; Carlos L Céspedes-Acuña; Julio Alarcón-Enos
Journal:  Molecules       Date:  2020-11-03       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.